Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of plasmapheresis on rituximab pharmacokinetics in autoimmune diseases
2008-000978-20Phase 4Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in autoimmune rheumatic diseases (ARDs) and autoimmune disease (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Started Apr 2008; status: active.
02
Drugs
rituximab
03
Conditions
autoimmune rheumatic diseases (ARDs)autoimmune disease
Beyond the preview
Go deeper on 2008-000978-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000978-20.